ILMN Illumina, Inc. Stock Quote

ILMN [NASD]

Healthcare | Diagnostics & Research | USA

Index	S&P 500	P/E	85.90	EPS (ttm)	5.20	Insider Own	0.20%	Shs Outstand	146.00M	Perf Week	-2.44%
Market Cap	65.72B	Forward P/E	89.26	EPS next Y	5.01	Insider Trans	-9.62%	Shs Float	145.52M	Perf Month	-12.46%
Income	768.00M	PEG	3.57	EPS next Q	1.13	Inst Own	91.80%	Short Float	1.51%	Perf Quarter	-2.01%
Sales	3.97B	P/S	16.57	EPS this Y	-34.10%	Inst Trans	-0.23%	Short Ratio	3.38	Perf Half Y	7.48%
Book/sh	35.48	P/B	12.60	EPS next Y	-12.80%	ROA	9.50%	Target Price	464.61	Perf Year	49.99%
Cash/sh	29.15	P/C	15.33	EPS next 5Y	24.03%	ROE	15.80%	52W Range	260.42 - 555.77	Perf YTD	20.81%
Dividend	-	P/FCF	73.19	EPS past 5Y	7.40%	ROI	6.50%	52W High	-19.57%	Beta	0.91
Dividend %	-	Quick Ratio	5.60	Sales past 5Y	7.90%	Gross Margin	68.60%	52W Low	71.65%	ATR	11.56
Employees	7800	Current Ratio	6.10	Sales Q/Q	77.90%	Oper. Margin	17.00%	RSI (14)	34.85	Volatility	2.00% 2.53%
Optionable	Yes	Debt/Eq	0.32	EPS Q/Q	296.30%	Profit Margin	19.40%	Rel Volume	2.68	Prev Close	449.92
Shortable	Yes	LT Debt/Eq	0.32	Earnings	Aug 05 AMC	Payout	0.00%	Avg Volume	648.10K	Price	447.01
Recom	2.80	SMA20	-3.82%	SMA50	-7.22%	SMA200	4.65%	Volume	1,739,491	Change	-0.65%

Aug-19-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

$425

Jun-01-21

Upgrade

Evercore ISI

Underperform → In-line

$400

Mar-31-21

Upgrade

Canaccord Genuity

Hold → Buy

$445

Mar-31-21

Downgrade

Atlantic Equities

Overweight → Neutral

$390

Mar-03-21

Initiated

Barclays

Underweight

$325

Dec-22-20

Upgrade

Piper Sandler

Neutral → Overweight

$340 → $415

Dec-17-20

Upgrade

BTIG Research

Neutral → Buy

$410

Oct-13-20

Downgrade

Guggenheim

Buy → Neutral

Sep-30-20

Initiated

Atlantic Equities

Overweight

$355

Sep-29-20

Downgrade

Wolfe Research

Outperform → Peer Perform

Sep-22-20

Downgrade

UBS

Buy → Neutral

$390 → $285

Sep-22-20

Downgrade

Stifel

Buy → Hold

$380 → $280

Sep-21-20

Upgrade

Guggenheim

Neutral → Buy

$345

Sep-21-20

Downgrade

JP Morgan

Overweight → Neutral

$390 → $280

Sep-09-20

Initiated

Morgan Stanley

Equal-Weight

$400

Aug-07-20

Downgrade

Piper Sandler

Overweight → Neutral

$356 → $340

Aug-07-20

Downgrade

Evercore ISI

In-line → Underperform

$310

Jul-07-20

Downgrade

Guggenheim

Buy → Neutral

Apr-24-20

Downgrade

Citigroup

Buy → Neutral

$250 → $320

Apr-21-20

Downgrade

Robert W. Baird

Outperform → Neutral

$310

Sep-16-21 07:30AM	Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team GlobeNewswire
Sep-15-21 09:15AM	Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle PR Newswire
Sep-14-21 07:30AM	Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura DAngelo as VP Investor Relations and Omar Elbakshish as Senior Director GlobeNewswire
Sep-13-21 02:56PM	UK's NHS Launches World's Largest Trial Of Blood Test For 50 Types Benzinga
Sep-12-21 07:01PM	Britain begins world's largest trial of blood test for 50 types of cancer Reuters
Sep-09-21 09:30AM	Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050 PR Newswire
Sep-08-21 08:36AM	Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal Zacks
Sep-07-21 10:38AM	Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay Benzinga
09:15AM	Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations PR Newswire
Sep-04-21 09:55AM	Why Illumina Wants Grail Back So Badly Motley Fool
Sep-03-21 07:30AM	Forget About the Genomic Revolution, the Proteomic Revolution Is Coming InvestorPlace
Sep-02-21 05:43PM	U.S. lawmakers question FTC's efforts to stop Illumina's deal for Grail Reuters
05:40PM	U.S. lawmakers question FTC's efforts to stop Illumina's deal for Grail Reuters
Aug-30-21 05:00PM	Illumina To Webcast Upcoming Investor Conference PR Newswire
Aug-27-21 07:01PM	Will Illuminas Purchase of Grail Kill Cancer-Test Competition? Barrons.com
Aug-26-21 11:32AM	Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges Zacks
Aug-24-21 03:30PM	FTC urges judge to unwind $7.1 billion Illumina-Grail merger Reuters
03:06PM	FTC urges judge to unwind $7.1 bln Illumina-Grail merger Reuters
07:38AM	The Strange Case of Illuminas Grail Acquisition and the Antitrust Trial That Beings Tuesday Barrons.com
Aug-23-21 09:00AM	INVESTOR ALERT. An Investor Investigation Is Underway Regarding Illuminas Closing of Its GRAIL Acquisition Without Obtaining EU Approval GlobeNewswire
07:46AM	Investors have very high Expectations for Illumina (NASDAQ:ILMN) and that will put the Share Price at Risk from Further Volatility Simply Wall St.
01:48AM	Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion Zacks
Aug-20-21 10:52AM	Illumina Just Dissed the European Commission. This Analyst Thinks That Was a Risky Move TipRanks
06:27AM	Illumina in EU antitrust sights over premature $8 billion Grail deal Reuters
06:22AM	UPDATE 2-Illumina in EU antitrust sights over premature $8 bln Grail deal Reuters
05:45AM	EU regulators to investigate Illumina's completion of Grail deal Reuters
04:02AM	Deere, Foot Locker and Spotify Rise Premarket Investing.com
Aug-19-21 04:02PM	Illumina Stock Nosedives After DNA Giant Makes A 'Maverick Move' In Its Grail Takeover Investor's Business Daily -7.88%
03:56PM	Why Illumina Stock Just Dropped 10% Motley Fool
01:55PM	Illumina's stock suffering biggest selloff in a year after warning of fines for closing GRAIL merger too soon MarketWatch
09:49AM	Illumina Completes Grail Buyout Despite Uncertainty In Regulatory Process Benzinga
07:37AM	The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga
06:39AM	Illumina Stock Stumbles on Analysts Reaction to Grail Deal TheStreet.com
06:18AM	UPDATE 1-Illumina decision to close Grail deal disappointing, EU says Reuters
05:29AM	EU disappointed at Illumina decision to close Grail deal despite antitrust probe Reuters
Aug-18-21 06:54PM	Illumina closes $7.1 billion deal for cancer test maker Grail amid regulatory hurdles Reuters
06:48PM	RPT-Illumina closes $7.1 bln deal for cancer test maker Grail amid regulatory hurdles Reuters
04:38PM	Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test PR Newswire
Aug-17-21 05:40PM	Illumina Stock Earns Membership In Elite Club Investor's Business Daily
Aug-14-21 08:12AM	Illumina Delivers a Beat and a Raise in Q2 Motley Fool
Aug-12-21 03:20PM	UPDATE 1-Illumina laments EU regulators' pause into Grail deal probe Reuters
08:30AM	If You Invested $1000 in Illumina 10 Years Ago, This Is How Much You'd Have Now Zacks
07:06AM	Best Growth Stocks September 2021 FX Empire
Aug-11-21 06:22AM	Forget Robinhood, These 3 Healthcare Stocks Are Better Buys Motley Fool
06:00AM	What Does the Future Look Like for Illumina Stock? Motley Fool
Aug-09-21 12:26PM	RiverPark Funds: Illumina (ILMN) has Two Large Growth Opportunities Ahead Insider Monkey
Aug-08-21 05:00PM	Why Does Illumina Want to Reunite With Grail? Motley Fool
Aug-06-21 12:45PM	Looking for a Growth Stock? 3 Reasons Why Illumina (ILMN) is a Solid Choice Zacks
10:07AM	Illumina (ILMN) Q2 Earnings Top Estimates, 2021 View Up Zacks
09:06AM	Illumina Stock Will Be Unstoppable Once the Grail Acquisition Gets Approved InvestorPlace
Aug-05-21 11:01PM	Illumina, inc (ILMN) Q2 2021 Earnings Call Transcript Motley Fool
05:25PM	Illumina (ILMN) Beats Q2 Earnings and Revenue Estimates Zacks
05:08PM	Illumina Offers Beat-And-Raise As The Hunt For Covid Variants Intensifies Investor's Business Daily
04:05PM	Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021 PR Newswire
Aug-04-21 12:52PM	Is Illumina (ILMN) an Interesting Stock to Buy? Insider Monkey
10:39AM	Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN Zacks
Aug-03-21 09:30PM	Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India PR Newswire
Jul-30-21 06:35AM	3 Things About Illumina That Smart Investors Know Motley Fool
Jul-29-21 03:05PM	Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
06:55AM	After Naming a New CFO, Is This Genetic Diagnostics Company a Buy? Motley Fool
Jul-28-21 06:30PM	Illumina to Webcast Upcoming Investor Conference Business Wire
Jul-26-21 08:50AM	How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener Zacks
Jul-23-21 12:28PM	Illumina-Grail $8B Merger Hit By European Commission's In-Depth Investigation Benzinga
06:00AM	Scottish Mortgage backs these vaccine pioneers to become the next Amazon The Telegraph
Jul-22-21 12:49PM	Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase Business Wire
12:39PM	Is Illumina (ILMN) A Smart Long-Term Buy? Insider Monkey
12:31PM	UPDATE 3-Illumina deal for Grail could hurt innovation, EU warns Reuters
12:19PM	Illumina deal for Grail could hurt innovation, EU warns Reuters
12:19PM	EU antitrust regulators to investigate Illumina, Grail deal Reuters
12:15PM	EU antitrust regulators to investigate Illumina, Grail deal Reuters
Jul-21-21 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Illumina (ILMN) Zacks
03:21AM	Is Illumina's (NASDAQ:ILMN) Share Price Gain Of 225% Well Earned? Simply Wall St.
Jul-20-21 12:10PM	Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive? Zacks
12:00PM	All You Need to Know About Illumina (ILMN) Rating Upgrade to Buy Zacks
Jul-19-21 07:07AM	Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy GlobeNewswire
Jul-14-21 11:50AM	Illumina, Grail Merger Faces Full-Scale European Probe Amid Antitrust Concerns: Reuters Benzinga
07:31AM	Is Illumina a Buy? Motley Fool
Jul-13-21 08:00PM	Competition enforcement is harder than it looks Financial Times
05:00PM	Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021 Business Wire
03:18PM	Exclusive-Illumina, Grail deal faces full-scale EU antitrust probe -sources Reuters
Jul-08-21 04:44PM	Why Illumina Was Up 17% in June Motley Fool
Jul-03-21 09:00AM	5 Top Stocks for July Motley Fool
Jun-30-21 11:30AM	Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
Jun-28-21 01:12PM	Investors Ritzy Habits Are Food for Thought for Insider Jury Bloomberg
Jun-25-21 11:58AM	Accused Fraudster Tapped Firm Account for Strip Club Visit Bloomberg
Jun-22-21 10:03AM	Illumina's (ILMN) NovaSeq Adoption Aids, Margin Woe Stays Zacks
Jun-18-21 08:22PM	Why Moderna, Illumina, or Meituan Could Be the Next Tesla Stock Barrons.com
04:13PM	Why Moderna, Illumina, or Chinas Meituan Could Be the Next Tesla Barrons.com
Jun-17-21 10:36AM	Hedge Funds Are Buying Illumina, Inc. (ILMN) Insider Monkey
05:34AM	EU antitrust regulators set July 27 deadline for Illumina, Grail deal Reuters
Jun-12-21 06:10AM	Has Illumina Lost Its Shine? Motley Fool
Jun-10-21 08:00AM	DNA Data Storage Alliance Publishes First White Paper, Launches Website Business Wire
06:43AM	The Zacks Analyst Blog Highlights: Intel, NextEra Energy, PetroChina, Illumina and Biogen Zacks
Jun-09-21 09:08AM	Let's Shine a Light on Illumina's Breakout TheStreet.com
06:47AM	Will Illumina Be a Trillion-Dollar Stock by 2035? Motley Fool
Jun-04-21 12:55PM	This Biotech Just Made History. Will Its Stock Follow? Motley Fool
09:09AM	Grail Will Begin Selling Its Multi-Cancer Blood Test. It Could Be the Start of a Huge Market. Barrons.com
08:37AM	2 Winners for a Drug Development Future That Looks Nothing Like the Past Motley Fool
Jun-01-21 07:40AM	Illumina (ILMN) Expands NIPT Offering With New Collaboration Zacks
03:05AM	Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis Business Wire

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TOUSI SUSAN H	SVP, Chief Commercial Officer	Aug 30	Sale	463.50	300	139,050	41,456	Sep 01 07:15 PM
Dadswell Charles	SVP & General Counsel	Aug 23	Sale	489.10	314	153,577	5,286	Aug 25 04:40 PM
Hoyt Aimee L	SVP, Chief People Officer	Aug 04	Sale	500.00	372	186,000	3,757	Sep 08 07:36 PM
TOUSI SUSAN H	SVP, Chief Commercial Officer	Aug 04	Sale	500.00	1,000	500,000	41,756	Aug 05 04:22 PM
TOUSI SUSAN H	SVP, Chief Commercial Officer	Jul 28	Sale	486.41	300	145,923	42,743	Jul 29 04:34 PM
Dadswell Charles	SVP & General Counsel	Jul 22	Sale	482.23	314	151,420	5,576	Jul 26 04:57 PM
Aravanis Alexander	SVP, Chief Technology Officer	Jul 07	Sale	477.59	539	257,421	4,679	Jul 07 06:26 PM
TOUSI SUSAN H	SVP, Chief Commercial Officer	Jun 28	Sale	478.95	300	143,685	43,043	Jun 30 05:27 PM
Hoyt Aimee L	SVP, Chief People Officer	Jun 24	Sale	475.00	500	237,500	4,111	Sep 08 07:36 PM
Dadswell Charles	SVP & General Counsel	Jun 22	Sale	461.01	314	144,757	5,890	Jun 24 05:41 PM
Febbo Phillip G.	SVP Chief Medical Officer	Jun 11	Sale	447.59	1,000	447,588	4,461	Jun 14 05:50 PM
DORSA CAROLINE	Director	Jun 10	Sale	450.00	1,000	450,000	8,501	Jun 14 05:48 PM
Hoyt Aimee L	SVP, Chief People Officer	Jun 10	Sale	450.00	500	225,000	4,611	Sep 08 07:36 PM
Dadswell Charles	SVP & General Counsel	May 24	Sale	403.04	314	126,555	6,204	May 26 04:50 PM
TOUSI SUSAN H	SVP, Chief Commercial Officer	May 20	Sale	400.00	500	200,000	43,343	May 24 04:43 PM
FLATLEY JAY T	Director	May 18	Sale	379.53	4,000	1,518,120	148,933	May 20 04:51 PM
TOUSI SUSAN H	SVP Product Development	May 05	Sale	381.88	300	114,564	43,843	May 06 05:26 PM
FLATLEY JAY T	Director	May 04	Sale	384.15	4,000	1,536,600	152,933	May 06 05:21 PM
Dadswell Charles	SVP & General Counsel	Apr 22	Sale	402.02	314	126,234	6,518	Apr 26 07:52 PM
FLATLEY JAY T	Director	Apr 20	Sale	401.83	4,000	1,607,320	156,933	Apr 22 05:05 PM
Hoyt Aimee L	SVP, Chief People Officer	Apr 06	Sale	424.22	1,000	424,218	5,111	Sep 08 07:36 PM
FLATLEY JAY T	Director	Apr 06	Sale	423.44	4,000	1,693,740	160,933	Apr 07 04:41 PM
TOUSI SUSAN H	SVP Product Development	Apr 06	Sale	423.44	500	211,718	44,143	Apr 07 04:34 PM
TOUSI SUSAN H	SVP Product Development	Apr 05	Sale	386.03	300	115,809	44,643	Apr 07 04:34 PM
Hoyt Aimee L	SVP, Chief People Officer	Apr 05	Sale	386.03	1,000	386,030	6,111	Sep 08 07:36 PM
Dadswell Charles	SVP & General Counsel	Mar 22	Sale	416.24	314	130,699	6,832	Mar 24 04:41 PM
FLATLEY JAY T	Director	Mar 16	Sale	421.06	4,000	1,684,240	164,933	Mar 18 07:20 PM
TOUSI SUSAN H	SVP Product Development	Mar 05	Sale	402.24	800	321,792	44,943	Mar 09 05:29 PM
FLATLEY JAY T	Director	Mar 02	Sale	444.61	4,000	1,778,440	168,933	Mar 04 05:04 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Feb 18	Sale	486.75	666	324,176	1,538	Feb 22 05:11 PM
TOUSI SUSAN H	SVP Product Development	Feb 17	Option Exercise	0.00	6,306	0	48,921	Feb 18 04:52 PM
SAMAD SAM	SVP and CFO	Feb 17	Option Exercise	0.00	4,379	0	9,355	Feb 18 04:51 PM
RAGUSA ROBERT P	SVP, Global Quality & Ops	Feb 17	Option Exercise	0.00	6,306	0	12,795	Feb 18 04:49 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Feb 17	Option Exercise	0.00	935	0	2,576	Feb 18 04:47 PM
Hoyt Aimee L	SVP, Chief People Officer	Feb 17	Option Exercise	0.00	4,625	0	8,873	Feb 18 04:45 PM
Febbo Phillip G.	SVP Chief Medical Officer	Feb 17	Option Exercise	0.00	3,173	0	7,046	Feb 18 04:44 PM
deSouza Francis A	President and CEO	Feb 17	Option Exercise	0.00	24,521	0	85,934	Feb 18 04:42 PM
Dadswell Charles	SVP & General Counsel	Feb 17	Option Exercise	0.00	3,503	0	8,781	Feb 18 04:41 PM
FLATLEY JAY T	Director	Feb 16	Sale	495.09	500	247,543	3,500	Feb 18 07:08 PM
FLATLEY JAY T	Director	Feb 16	Sale	505.26	4,000	2,021,040	172,933	Feb 18 07:08 PM
TOUSI SUSAN H	SVP Product Development	Feb 05	Sale	431.90	800	345,520	39,713	Feb 09 04:48 PM
Hoyt Aimee L	SVP, Chief People Officer	Feb 02	Sale	444.84	57	25,356	2,359	Feb 03 05:00 PM
FLATLEY JAY T	Director	Feb 02	Sale	444.84	4,000	1,779,360	176,933	Feb 03 04:58 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Feb 02	Sale	444.84	72	32,028	1,538	Feb 03 04:57 PM
deSouza Francis A	President and CEO	Feb 01	Sale	439.78	3,000	1,319,330	52,603	Feb 03 04:56 PM
TOUSI SUSAN H	SVP Product Development	Jan 20	Sale	400.00	2,500	1,000,000	40,447	Jan 21 04:40 PM
FLATLEY JAY T	Director	Jan 19	Sale	382.48	4,000	1,529,920	180,933	Jan 21 04:38 PM
Hoyt Aimee L	SVP, Chief People Officer	Jan 11	Sale	379.65	271	102,885	2,359	Jan 12 04:41 PM
TOUSI SUSAN H	SVP Product Development	Jan 05	Sale	365.27	300	109,581	42,947	Jan 06 07:20 PM
FLATLEY JAY T	Director	Jan 05	Sale	365.27	4,000	1,461,080	184,933	Jan 06 07:19 PM
deSouza Francis A	President and CEO	Jan 04	Sale	370.51	3,000	1,111,537	55,540	Jan 06 07:17 PM
FLATLEY JAY T	Director	Dec 15	Sale	348.84	4,000	1,395,360	188,933	Dec 16 06:07 PM
Hoyt Aimee L	SVP, Chief People Officer	Dec 14	Sale	345.00	354	122,130	2,744	Dec 16 06:05 PM
Ronaghi Mostafa	SVP, Entrepreneurial Devlopmt	Dec 10	Sale	338.58	5,000	1,692,922	80,162	Dec 14 04:12 PM
TOUSI SUSAN H	SVP Product Development	Dec 07	Sale	349.34	300	104,803	43,247	Dec 08 05:34 PM
TOUSI SUSAN H	SVP Product Development	Dec 04	Sale	350.00	200	70,000	43,547	Dec 08 05:34 PM
Dadswell Charles	SVP & General Counsel	Dec 01	Sale	323.86	1,694	548,619	3,460	Dec 02 05:48 PM
deSouza Francis A	President and CEO	Dec 01	Sale	327.95	3,000	983,851	58,540	Dec 02 05:45 PM
TOUSI SUSAN H	SVP Product Development	Dec 01	Sale	325.00	100	32,500	43,747	Dec 02 05:41 PM
FLATLEY JAY T	Director	Dec 01	Sale	323.90	4,000	1,295,590	192,933	Dec 02 05:37 PM
RAGUSA ROBERT P	SVP, Global Quality & Ops	Nov 30	Sale	314.82	2,890	909,827	4,092	Dec 02 05:34 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Nov 18	Sale	300.00	218	65,400	1,538	Nov 19 04:16 PM
FLATLEY JAY T	Director	Nov 17	Sale	297.16	3,000	891,470	196,933	Nov 19 04:18 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Nov 06	Sale	310.10	312	96,751	1,872	Nov 09 05:40 PM
Hoyt Aimee L	SVP, Chief People Officer	Nov 06	Sale	310.10	215	66,672	3,098	Nov 09 05:39 PM
Febbo Phillip G.	SVP Chief Medical Officer	Nov 06	Sale	310.10	155	48,066	2,143	Nov 09 05:35 PM
FLATLEY JAY T	Director	Nov 03	Sale	297.34	3,000	892,010	199,933	Nov 04 04:43 PM
deSouza Francis A	President and CEO	Nov 02	Sale	300.28	3,000	900,852	65,840	Nov 04 04:39 PM
Dadswell Charles	SVP & General Counsel	Nov 02	Sale	298.00	121	36,058	6,036	Nov 04 04:34 PM
FLATLEY JAY T	Director	Oct 20	Sale	321.71	4,000	1,286,860	202,933	Oct 22 03:47 PM
TOUSI SUSAN H	SVP Product Development	Oct 12	Sale	350.00	200	70,000	44,968	Oct 14 04:07 PM
TOUSI SUSAN H	SVP Product Development	Oct 07	Sale	325.00	100	32,500	45,168	Oct 08 05:21 PM
FLATLEY JAY T	Director	Oct 07	Sale	324.01	1,000	324,010	206,933	Oct 08 05:18 PM
FLATLEY JAY T	Director	Oct 06	Sale	317.79	3,000	953,370	207,933	Oct 07 04:49 PM
deSouza Francis A	President and CEO	Oct 01	Sale	308.78	3,000	926,331	68,840	Oct 05 05:14 PM
Dadswell Charles	SVP & General Counsel	Oct 01	Sale	312.82	121	37,851	6,157	Oct 05 05:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience